Back to Search
Start Over
Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine
- Source :
- Plus Company Updates. February 8, 2018
- Publication Year :
- 2018
-
Abstract
- Oakland: Allergan has issued the following press release: Allergan plc , (NYSE: AGN), a leading global pharmaceutical company today announced positive results from ACHIEVE I (UBR-MD-01), the first of two [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Plus Company Updates
- Publication Type :
- News
- Accession number :
- edsgcl.526753570